Abbvie Inc. vs Boston Scientific Corp.
ABBV vs BSX — side-by-side comparison from reported financials. ABBV leads 5, BSX leads 7 of 12 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
Boston Scientific Corp.
BSX · Healthcare
$42.62+1.37%Solid
| Metric | ABBV | BSX |
|---|---|---|
| Price | $276.43 | $42.62 |
| Market cap | $488B | $61.8B |
| Revenue (TTM) | $64.4B | $21.0B |
| Revenue growth | +1.8% | +16.5% |
| Net margin | 9.8% | 17.5% |
| Free cash flow | $18.2B | $3.63B |
| Net cash (debt) | ($56.2B) | ($9.47B) |
| 1-year price return | +19.8% | -56.2% |
| P/E | 77.4 | 16.9 |
| P/E vs own history (cheap-side %) | 23% | 99% |
| Dividend yield | 2.45% | 0.00% |
| Return on equity | 96% | 15% |
| Altman Z-score | 2.33 | 2.58 |
| CV checks passed | 9 of 11 | 10 of 11 |
| Employees | 57,000 | 59,000 |
Full résumé-style profiles: ABBV CV · BSX CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.